posted on 2018-12-10, 00:00authored byPayal Rana, Michael D. Aleo, Mark Gosink, Yvonne Will
Mitochondrial toxicity
has been shown to contribute to a variety
of organ toxicities such as liver, cardiac, and kidney. In the past
decades, two high-throughput applicable screening assays (isolated
rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess
mitochondrial toxicity have been deployed in many pharmaceutical companies,
and numerous publications have demonstrated its usefulness for mechanistic
investigations. However, only two publications have demonstrated the
utility of these screens as a predictor of human drug-induced liver
injury. In the present study, we screened 73 hepatotoxicants, 46 cardiotoxicants,
49 nephrotoxicants, and 60 compounds not known to cause human organ
toxicity for their effects on mitochondrial function(s) in the assays
mentioned above. Predictive performance was evaluated using specificity
and sensitivity of the assays for predicting organ toxicity. Our results
show that the predictive performance of the mitochondrial assays are
superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity
(sensitivity 63% vs 33% and 28% with similar specificity of 93%),
when the analysis was done at 100* Cmax (drug concentration in human
plasma level). We further explored the association of mitochondrial
toxicity with physicochemical properties such as calculated log partition
coefficient (cLogP), topological polar surface area, ionization status,
and molecular weight of the drugs and found that cLogP was most significantly
associated mitochondrial toxicity. Since these assays are amenable
to higher throughput, we recommend that chemists use these assays
to perform structure activity relationship early in the drug discovery
process, when chemical matter is abundant. This assures that compounds
that lack the propensity to cause mitochondrial dysfunction (and associated
organ toxicity) will move forward into animals and humans.